Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Marker Therapeutics stock

MRKR
US57055L2060
A2N7XT

Price

1.57
Today +/-
-0.06
Today %
-3.75 %

Marker Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Marker Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Marker Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Marker Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Marker Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Marker Therapeutics Stock Price History

DateMarker Therapeutics Price
2/20/20251.57 undefined
2/19/20251.63 undefined
2/18/20251.55 undefined
2/17/20251.57 undefined
2/13/20251.72 undefined
2/12/20251.70 undefined
2/11/20251.59 undefined
2/10/20251.55 undefined
2/9/20251.72 undefined
2/6/20251.77 undefined
2/5/20251.95 undefined
2/4/20252.02 undefined
2/3/20251.88 undefined
2/2/20251.79 undefined
1/30/20251.84 undefined
1/29/20251.92 undefined
1/28/20251.93 undefined
1/27/20252.09 undefined
1/26/20251.93 undefined

Marker Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Marker Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Marker Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Marker Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Marker Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Marker Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Marker Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Marker Therapeutics’s growth potential.

Marker Therapeutics Revenue, EBIT and net profit per share

DateMarker Therapeutics RevenueMarker Therapeutics EBITMarker Therapeutics Net Income
2029e36.72 M undefined0 undefined0 undefined
2028e24.48 M undefined0 undefined0 undefined
2027e38.73 M undefined-41.83 M undefined-12.34 M undefined
2026e0 undefined-60.18 M undefined-29.77 M undefined
2025e2.04 M undefined-46.24 M undefined-25.31 M undefined
2024e9.78 M undefined4.31 M undefined-7.11 M undefined
20233.31 M undefined-14.58 M undefined-8.24 M undefined
20229.01 M undefined-29.95 M undefined-29.93 M undefined
20211.24 M undefined-39.47 M undefined-41.88 M undefined
2020470,000 undefined-28.89 M undefined-28.71 M undefined
2019210,000 undefined-22.53 M undefined-21.43 M undefined
2018210,000 undefined-148.17 M undefined-147.96 M undefined
20170 undefined-11.66 M undefined-10.98 M undefined
20160 undefined-8.49 M undefined-2.46 M undefined
20150 undefined-6.16 M undefined-34.07 M undefined
20140 undefined-3.38 M undefined-30.88 M undefined
20130 undefined-2.66 M undefined-5.53 M undefined
20120 undefined-5.48 M undefined-6.17 M undefined
20110 undefined-2.64 M undefined-2.03 M undefined
20100 undefined-4.23 M undefined-3.53 M undefined
20090 undefined-4.19 M undefined-17.6 M undefined
20080 undefined-1.5 M undefined-2.2 M undefined
20070 undefined-2.51 M undefined-3.89 M undefined
20060 undefined-890,000 undefined-1.31 M undefined
20050 undefined-1.01 M undefined-990,000 undefined
20040 undefined-2.59 M undefined-2.68 M undefined

Marker Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000000000000000193920382436
-----------------------800.00-66.67200.00-77.78---36.8450.00
-------------------------------
0000000000000000000000000000000
000-2-5-20-1-3-2-17-3-2-6-5-30-34-2-10-147-21-28-41-29-8-7-25-29-1200
----150.00-60.00--200.00-33.33750.00-82.35-33.33200.00-16.67500.0013.33-94.12400.001,370.00-85.7133.3346.43-29.27-72.41-12.50257.1416.00-58.62--
00000000000000.010.010.130.370.690.951.914.564.77.658.358.81000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Marker Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Marker Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                 
0.180.190.010.640.020.010.060.120.1700.140.020.250.030.050.146.587.855.1361.7543.921.3542.3511.7815.11
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
0000.01000.0300.040.010.2100.060.060.030.080.070.070.050.141.532.063.632.440.99
0.180.190.010.650.020.010.090.120.210.010.350.020.310.090.080.226.657.925.1861.8945.4323.4145.9814.2216.1
00.110.150.110.070.040.0100.020.010000000000.150.8721.222.1517.80
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
0000040000009030000000000000
00.110.150.110.070.080.0100.020.0100.090.030000000.150.8721.222.1517.80
0.180.30.160.760.090.090.10.120.230.020.350.110.340.090.080.226.657.925.1862.0446.344.6168.1332.0216.1
                                                 
010102020203010903505508041043002070101050505080108.89
0.181.261.614.439.1410.0411.2411.7516.9117.537.2937.8139.9443.4846.7285.27112.08151.99161.07365.4371.57383.53442.02447.64450.33
-0.08-1.02-1.69-3.97-9.75-12.44-13.42-14.73-18.62-20.81-38.41-41.69-43.72-49.89-55.43-86.31-133.51-145.82-157.42-306.11-327.53-356.24-398.12-428.05-436.29
000-0.01-0.05-0.06-0.07-0.04-0.06-0.06-0.06-0.06-0.1-0.06-0.060000000000
0000000000000000000000000
0.10.25-0.070.47-0.64-2.44-2.22-3.01-1.68-3.02-0.63-3.86-3.47-6.04-8.77-1.02-21.366.183.6659.3444.0927.3443.9819.614.05
0.070.050.160.30.381.241.091.341.252.010.611.071.112.311.820.620.971.221.512.341.433.348.182.371.75
000000000000002.330.070000.420.533.063.572.910
00000.360.810.670.150.20.240.052.141.582.261.220.526.990.510.010.050.0301.152.51.33
000000.480.480.580.30.820.340.430.111.553.480.050.050.010.01000000
0.0100.070000.061.090.20000000000000000
0.080.050.230.30.742.532.33.161.953.0713.642.86.128.851.2428.011.741.532.811.996.412.97.783.07
000000000003501,000000000000000
0000000000000000000000000
000000000000000000000.2811.8711.257.040
000000000000.35100000000.2811.8711.257.040
0.080.050.230.30.742.532.33.161.953.0713.993.86.128.851.2428.011.741.532.812.2718.2724.1514.823.07
0.180.30.160.770.10.090.080.150.270.050.370.130.330.080.080.226.657.925.1962.1546.3645.6168.1334.4217.13
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Marker Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Marker Therapeutics's financial health and stability.

Assets

Marker Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Marker Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Marker Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Marker Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000-2-5-20-1-3-2-17-3-2-5-5-30-34-2-10-147-21-28-41-29-8
0000000000000000000000220
0000000000000000000000000
00000100000102200001-225-52
00002000201510222829-421325565-11
0000000000000000000000000
0000000000000000000000000
000-1-2-1-1-1-10-10-1-10-2-4-6-8-14-18-20-27-26-16
000000000000000000000-9-3-40
000000000000000000000-9-3-418
00000000000000000000000018
0000000000000000000000000
0000000000000000000000000
0101101100000001116571065201
0101211110101102107571065201
000000000000000001,0000000000
0000000000000000000000000
000000000000000061-256-17-2222-313
-0.06-1.06-0.67-1.42-2.59-1.29-1.17-1.43-1.27-0.72-1.12-0.93-1.31-1.57-0.69-2.19-4.34-6.51-8.44-14.63-18.65-29.28-30.41-31.92-16.44
0000000000000000000000000

Marker Therapeutics stock margins

The Marker Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Marker Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Marker Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Marker Therapeutics's sales revenue. A higher gross margin percentage indicates that the Marker Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Marker Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Marker Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Marker Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Marker Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Marker Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Marker Therapeutics Margin History

Marker Therapeutics Gross marginMarker Therapeutics Profit marginMarker Therapeutics EBIT marginMarker Therapeutics Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %-108 %-31.87 %
2026e0 %0 %0 %
2025e0 %-2,266.9 %-1,240.75 %
2024e0 %44.08 %-72.71 %
20230 %-440.37 %-248.76 %
20220 %-332.41 %-332.19 %
20210 %-3,183.06 %-3,377.42 %
20200 %-6,146.81 %-6,108.51 %
20190 %-10,728.57 %-10,204.76 %
20180 %-70,557.15 %-70,457.15 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %

Marker Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Marker Therapeutics earnings per share therefore indicates how much revenue Marker Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Marker Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Marker Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Marker Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Marker Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Marker Therapeutics Revenue, EBIT and net profit per share

DateMarker Therapeutics Sales per ShareMarker Therapeutics EBIT per shareMarker Therapeutics Earnings per Share
2029e3.43 undefined0 undefined0 undefined
2028e2.29 undefined0 undefined0 undefined
2027e3.62 undefined0 undefined-1.15 undefined
2026e0 undefined0 undefined-2.78 undefined
2025e0.19 undefined0 undefined-2.36 undefined
2024e0.91 undefined0 undefined-0.66 undefined
20230.38 undefined-1.66 undefined-0.94 undefined
20221.08 undefined-3.59 undefined-3.58 undefined
20210.16 undefined-5.16 undefined-5.47 undefined
20200.1 undefined-6.15 undefined-6.11 undefined
20190.05 undefined-4.94 undefined-4.7 undefined
20180.11 undefined-77.58 undefined-77.47 undefined
20170 undefined-12.27 undefined-11.56 undefined
20160 undefined-12.3 undefined-3.57 undefined
20150 undefined-16.65 undefined-92.08 undefined
20140 undefined-26 undefined-237.54 undefined
20130 undefined-266 undefined-553 undefined
20120 undefined-548 undefined-617 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Marker Therapeutics business model

Marker Therapeutics is one of the most popular companies on Eulerpool.com.

Marker Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Marker Therapeutics Revenue by Segment

Segmente202120192018
Grant income1.24 M USD--
Grant-213,194 USD205,994 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Marker Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Marker Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Marker Therapeutics shares outstanding

The number of shares was Marker Therapeutics in 2024 — This indicates how many shares 8.809 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Marker Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Marker Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Marker Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Marker Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Marker Therapeutics stock splits

In Marker Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Marker Therapeutics.

Marker Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.4 -0.26  (34.64 %)2024 Q3
6/30/2024-0.44 -0.25  (43 %)2024 Q2
3/31/2024-0.26 -0.27  (-5.06 %)2024 Q1
12/31/2022-1.02 -0.48  (52.94 %)2022 Q4
9/30/2022-1.22 -0.8  (34.64 %)2022 Q3
6/30/2022-1.29 -1.1  (14.86 %)2022 Q2
3/31/2022-1.36 -1.2  (11.76 %)2022 Q1
12/31/2021-1.3 -1.2  (7.73 %)2021 Q4
9/30/2021-1.3 -1.2  (7.73 %)2021 Q3
6/30/2021-1.2 -1.3  (-8.47 %)2021 Q2
1
2
3

Eulerpool ESG Scorecard© for the Marker Therapeutics stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

45

👫 Social

33

🏛️ Governance

43

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Marker Therapeutics shareholders

%
Name
Stocks
Change
Date
15.17907 % New Enterprise Associates (NEA)1,625,678554,25012/31/2024
8.54894 % Alyeska Investment Group, L.P.915,591915,59112/31/2024
7.29412 % Wilson (John Robert)781,200012/31/2024
5.17507 % Blue Owl Capital Holdings LP554,250554,25012/31/2024
3.09683 % Hudson Bay Capital Management LP331,670331,67012/31/2024
3.03800 % Aisling Capital Management LP325,37011,08412/31/2024
2.49472 % Vera (Juan F. M.D.)267,184012/31/2024
2.27005 % The Vanguard Group, Inc.243,122012/31/2024
0.74444 % LPL Financial LLC79,73079,73012/31/2024
0.70663 % Geode Capital Management, L.L.C.75,6804,11912/31/2024
1
2
3
4
5
...
7

Marker Therapeutics Executives and Management Board

Dr. Juan Vera

(43)
Marker Therapeutics President, Chief Executive Officer, Principal Financial and Accounting Officer, Director (since 2018)
Compensation 581,923

Mr. N. David Eansor

(62)
Marker Therapeutics Independent Chairman of the Board
Compensation 93,316

Mr. Steven Elms

(59)
Marker Therapeutics Independent Director
Compensation 71,700

Mr. John Wilson

(63)
Marker Therapeutics Independent Director
Compensation 67,200

Dr. Katharine Knobil

(59)
Marker Therapeutics Independent Director
Compensation 62,711
1
2

Marker Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bio-Techne Stock
Bio-Techne
SupplierCustomer0,350,620,810,700,58-0,01
1

Most common questions regarding Marker Therapeutics

What is the P/E ratio of Marker Therapeutics 2025?

The Marker Therapeutics P/E ratio is -0.55.

What is the P/S ratio of Marker Therapeutics 2025?

The Marker Therapeutics P/S ratio is 6.78.

What is the Quality Investing of Marker Therapeutics?

The Quality Investing for Marker Therapeutics is 5/10.

What is the revenue of Marker Therapeutics 2025?

The expected Marker Therapeutics revenue is 2.04 M USD.

How high is the profit of Marker Therapeutics 2025?

The expected Marker Therapeutics profit is -25.31 M USD.

What is the business model of Marker Therapeutics

No history available for Marker Therapeutics.

What is the Marker Therapeutics dividend?

Marker Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Marker Therapeutics pay dividends?

The dividend cannot currently be calculated for Marker Therapeutics or the company does not pay out a dividend.

What is the Marker Therapeutics ISIN?

The ISIN of Marker Therapeutics is US57055L2060.

What is the Marker Therapeutics WKN?

The WKN of Marker Therapeutics is A2N7XT.

What is the Marker Therapeutics ticker?

The ticker of Marker Therapeutics is MRKR.

How much dividend does Marker Therapeutics pay?

Over the past 12 months, Marker Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Marker Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Marker Therapeutics?

The current dividend yield of Marker Therapeutics is .

When does Marker Therapeutics pay dividends?

Marker Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Marker Therapeutics?

Marker Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Marker Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Marker Therapeutics located?

Marker Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Marker Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Marker Therapeutics from 2/23/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/23/2025.

When did Marker Therapeutics pay the last dividend?

The last dividend was paid out on 2/23/2025.

What was the dividend of Marker Therapeutics in the year 2024?

In the year 2024, Marker Therapeutics distributed 0 USD as dividends.

In which currency does Marker Therapeutics pay out the dividend?

The dividends of Marker Therapeutics are distributed in USD.

All fundamentals about Marker Therapeutics

Our stock analysis for Marker Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Marker Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.